A two-part, randomized, double-blind, placebo-controlled Phase 2 study of SENS-401 in severe or profound sudden sensorineural hearing loss

Phase 2, randomised, double-blind trial in acute sensorineural hearing loss and sensorineural hearing loss (SNHL) comparing SENS-401 with Placebo (2 arms). Primary endpoint: Primary: Change in PTA (3 most affected contiguous frequencies) from baseline to Day 28. Started Jul 2018; status: completed.